Safety and effectiveness of isavuconazole in real-life non-neutropenic patients.

Autores de IIS La Fe

• Julio Garcia Rodriguez

  Autor

• Javier Pemán García

  Autor

• Miguel Salavert Lletí

  Autor

Participantes ajenos a IIS La Fe

• Monzo-Gallo, Patricia
• Lopera, Carlos
• Badia-Tejero, Ana M
• Machado, Marina
• Vidal-Cortes, Pablo
• Merino, Esperanza
• Calderon, Jorge
• Fortun, Jesus
• Palacios-Baena, Zaira R
• Sanchis, Joan Roig
• Aguilar-Guisado, Manuela
• Gudiol, Carlota
• Ramos, Juan C
• Sanchez-Romero, Isabel
• Martin-Davila, Pilar
• Lopez-Cortes, Luis E
• Ruiz-Camps, Isabel
• Chumbita, Mariana
• Aiello, Tommaso Francesco
• Peyrony, Olivier
• Puerta-Alcalde, Pedro
• Soriano, Alex
• Marco, Francesc
• Garcia-Vidal, Carolina

Grupos

• Infección Grave

Abstract

OBJECTIVES: Information is scarce on clinical experiences with non-neutropenic patients with invasive fungal infection (IFI) receiving isavuconazole. We aimed to report the safety and effectiveness of this drug as a first-line treatment or rescue in real life. METHODS: A retrospective, observational multicentric study of non-neutropenic patients who received isavuconazole as an IFI treatment at 12 different university hospitals (January 2018-2022). All patients met criteria for proven, probable or possible IFI according to EORTC-MSG. RESULTS: A total of 238 IFIs were treated with isavuconazole during the study period. Combination therapy was administered in 27.7% of cases. The primary IFI was aspergillosis (217, 91.2%). Other IFIs treated with isavuconazole were candidemia (n = 10), mucormycosis (n = 8), histoplasmosis (n = 2), cryptococcosis (n = 2), and others (n = 4). Median time of isavuconazole treatment was 29 days. Only 5.9% (n = 14) of cases developed toxicity, mainly hepatic-related (10 patients, 4.2%). Nine patients (3.8%) had treatment withdrawn. Successful clinical response at 12 weeks was documented in 50.5% of patients. CONCLUSION: Isavuconazole is an adequate treatment for non-neutropenic patients with IFIs. Toxicity rates were low and its effectiveness was comparable to other antifungal therapies previously reported.

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Keywords

• Effectiveness; Invasive fungal infection; Isavuconazole; Non-neutropenic; Safety